News


All series


All News

There has been renewed interest in eribulin mesylate (Halaven) following its FDA approval for advanced or unresectable liposarcoma and with the introduction of a growing body of preclinical work suggesting the agent has a novel anti–mesenchymal mechanism of action.

Findings of a recent randomized trial showed patients with myelofibrosis and thrombocytopenia had significantly greater reductions in spleen volume and symptoms when treated with the multikinase inhibitor pacritinib, compared with the best available therapy (BAT).

The next-generation BTK inhibitor acalabrutinib produced an objective response rate (ORR) of 38.1% as a monotherapy for patents with Richter transformation (RT), according to findings from the phase I/II ACE-CL-001 study presented at the 2016 ASH Annual Meeting.

While mouse models have historically been helpful in the research of immunotherapies, genetic testing and clinical models may play a role in the near future.&nbsp;These pre-clinical models have been criticized for some of their limitations, but Marcus Bosenberg, MD, PhD, confirms their current relevance and clinical applicability.<br /> &nbsp;

The FDA has granted a full approval and label update to ponatinib (Iclusig) for patients with chronic phase (CP), accelerated phase, or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).